1 Safety was also analysed in the intention-to treat population
2 Flurpiridaz
safety was also evaluated.
3 Safety was analysed in all participants who received at least
4 Safety was analysed in all patients who started their allocat
5 Safety was analysed in patients who received at least one dos
6 Safety was analyzed in all patients who received at least one
7 Safety was analyzed in all randomized patients who received s
8 cylinders obtained and the percentage of adequate biopsies;
safety was analyzed in terms of the percentage of complicatio
9 Safety was assessed by adverse events (AEs), laboratory tests
10 nts with at least one available set of on-treatment images;
safety was assessed in a per-protocol population.
11 Safety was assessed in all eligible treated study participant
12 Safety was assessed in all participants who received at least
13 d at least 26 weeks before data cutoff (June 27, 2019), and
safety was assessed in all participants who received at least
14 Safety was assessed in all participants who received at least
15 s assessed in all patients with available blood samples and
safety was assessed in all participants.
16 Safety was assessed in all patients according to which treatm
17 Safety was assessed in all patients for whom study treatment
18 Safety was assessed in all patients from the dose-escalation
19 Safety was assessed in all patients per treatment received.
20 Safety was assessed in all patients who had at least one dose
21 Safety was assessed in all patients who had received at least
22 Safety was assessed in all patients who had received at least
23 Safety was assessed in all patients who received at least one
24 In both groups,
safety was assessed in all patients who received at least one
25 Safety was assessed in all patients who received at least one
26 Safety was assessed in all patients who received at least one
27 Safety was assessed in all patients who received at least one
28 Safety was assessed in all patients who received study drug.
29 Safety was assessed in all patients.
30 Safety was assessed in all randomised patients.
31 Safety was assessed in mothers and infants until 24 weeks pos
32 analysis was done in the intention-to-treat population and
safety was assessed in patients who received at least one dos
33 analysis was done in the intention-to-treat population and
safety was assessed in patients who received at least one dos
34 Safety was assessed in the full analysis set.
35 Safety was assessed in the modified intention-to-treat popula
36 Safety was assessed in the total vaccinated population-ie, al
37 Safety was assessed over 28 days after vaccination.
38 Safety was assessed through adverse event and laboratory data
39 Safety was assessed up to 48 h post-injection.
40 Overall
safety was comparable between OH+ (n = 288, 27.5%) and OH- (n
41 Safety was compared across treatment groups for all patients
42 Safety was evaluated by adverse events and ACM through follow
43 gh)) were based on reference adult pharmacokinetic data and
safety was evaluated in all children in the corresponding wei
44 eafter, the "outbreak strain") were determined, and vaccine
safety was evaluated.
45 Safety was gauged as a decline or change from baseline in any
46 Primary
safety was major adverse events through 30 days.
47 The primary end point of efficacy and
safety was not different between the 2 groups (55.1% versus 4
48 sustained for almost 2 months and the material efficacy and
safety was proven both in vitro and in vivo.
49 Safety was similar between treatment groups, and in line with
50 Safety was the primary end point and was determined by incide